Activ Surgical today received a $15 million extension to its Series B financing round, bringing its total Series B to $60 million. Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures, led the Series B extension, which also had participation from existing investors. The $15 million investment announced today adds to the initial $45 million Boston-based Activ […]
Hikma Pharmaceuticals PLC
GSK dodges bullet after another generic Advair competitor is denied
GlaxoSmithKline (NYSE:GSK) will not likely face generic competition to its lung drug Advair in the US this year. Yesterday, the FDA denied the application for a 2nd generic competitor. Hikma Pharmaceuticals (LON:HIK) disclosed today that the FDA decided not to approve its version of the inhaled asthma treatment, due to “major” problems with the application. This comes […]